in contrast , in poor-prognosis patients with non-hodgkin 's lymphoma , hodgkin 's disease , multiple myeloma , or neuroblastoma , high-dose melphalan-containing regimens have yielded both high response rates and improved survival , despite considerable toxicity .
C0027819
neuroblastoma
C0025241
melphalan